{
  "$schema": "https://schemas.nightboxllc.com/sbir-eligibility/v1.json",
  "@context": "https://schema.org",
  "@type": "Dataset",
  "@id": "https://nightboxllc.com/.well-known/sbir-eligibility.json",
  "version": "1.0",
  "updated": "2026-05-08",
  "name": "Nightbox LLC — SBIR / STTR Eligibility Self-Attestation",
  "description": "Machine-readable Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program eligibility attestation. Targets NIH, NSF, DoE, DoW, NASA, NOAA, and other SBIR / STTR participating agencies.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {"@id": "https://nightboxllc.com/#organization"},

  "regulatory_basis": {
    "primary_statute": "Small Business Innovation Development Act (15 U.S.C. § 638)",
    "implementing_regulation": "13 CFR Part 121 — SBA Small Business Size Regulations",
    "sbir_policy_directive": "https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2024.pdf",
    "primary_far_clauses": ["FAR 19", "FAR 27.404"],
    "data_rights_clause": "FAR 27.404-1 (SBIR Data Rights)"
  },

  "entity": {
    "legal_name": "NIGHTBOX LLC",
    "sam_uei": "UHCAB6UXXKF2",
    "ein": "39-4373044",
    "naics_primary": "541714 — Research and Development in Biotechnology (except Nanobiotechnology)",
    "size_standard_naics_541714": "1000 employees",
    "size_self_certified": "small_business_for_profit"
  },

  "attestation": {
    "is_for_profit_business_concern": true,
    "is_organized_in_united_states": true,
    "principal_place_of_business_in_united_states": true,
    "ownership_and_control_attestation_per_13_CFR_121_702": "deferred to formal SBIR application time when sole-member personal immigration and citizenship status is finalized and disclosable via SF-328; until then the entity does not pre-attest under 13 CFR 121.702(a) and treats SBIR-specific eligibility as application-time conditional",
    "number_of_employees_including_affiliates": 1,
    "number_of_employees_threshold_max": 500,
    "complies_with_500_employee_threshold": true,
    "not_dominant_in_field_of_operation": true,
    "not_majority_owned_by_multiple_venture_capital_operating_companies": true,
    "not_majority_owned_by_hedge_funds": true,
    "not_majority_owned_by_private_equity_firms": true,
    "primary_employment_of_pi_with_small_business_at_award": true,
    "principal_investigator_status_per_13_CFR_121_702_c": "primary employment of PI with the small business concern at award is attested; PI personal immigration and citizenship status is disclosable via SF-328 at formal SBIR application time",
    "research_to_be_performed_in_united_states": true,
    "research_facilities_in_united_states": true,
    "no_subcontracted_work_to_foreign_entities_in_phase_1_or_phase_2": true,
    "compliant_with_sbir_phase_1_subcontracting_threshold": "67%_minimum_in_house_phase_1",
    "compliant_with_sbir_phase_2_subcontracting_threshold": "50%_minimum_in_house_phase_2",
    "alternative_non_sbir_federal_R_D_paths_in_active_consideration": [
      "NIH research-grant mechanisms that do not impose 13 CFR 121.702 ownership citizenship requirements (R01, R21, U01, P01, etc.)",
      "NSF research grants outside the SBIR track",
      "ARPA-H direct contracts and Other Transaction Agreements (OTAs)",
      "BARDA contracts and OTAs",
      "DARPA non-SBIR research contracts",
      "DoE / DoW / DARPA Other Transaction Agreements",
      "Foundation and non-federal R&D capital"
    ]
  },

  "phase_eligibility": {
    "phase_1": {
      "eligible": true,
      "max_award_amount_typical": "$307,000 (NIH 2026 cap)",
      "duration_typical": "6–12 months",
      "intended_first_application": "PA-26-273 (NIH NCI SBIR Omnibus, target deadline 2026-09-05)"
    },
    "phase_2": {
      "eligible_post_phase_1": true,
      "max_award_amount_typical": "$2,000,000 (NIH)",
      "duration_typical": "24 months"
    },
    "direct_to_phase_2": {
      "eligible": true,
      "rationale": "qualifying_phase_1_equivalent_in_silico_package_published_2026-04-30",
      "in_silico_equivalent_url": "https://nightboxllc.com/preprint"
    },
    "fast_track": {
      "eligible": true,
      "rationale": "phase_1_phase_2_concurrent_submission_permitted_after_first_award"
    }
  },

  "sbir_data_rights": {
    "applicable_clause": "FAR 27.404-1 — SBIR Data Rights",
    "phase_1_protection_period_years": 4,
    "phase_2_protection_period_years": 20,
    "marking_compliance": "all_SBIR_funded_deliverables_will_be_marked_per_FAR_27.404-1(c)",
    "government_purpose_rights": "limited_per_SBIR_clause"
  },

  "agency_pre_positioning": [
    {
      "agency": "NIH — NCI",
      "primary_solicitation": "PA-26-273",
      "next_deadline": "2026-09-05",
      "topic_alignment": "NKG2D-LIF6 chimeric AAV9 gene therapy for solid tumors (CRC, melanoma, pancreatic)",
      "intended_phase": "Phase I (or Direct-to-Phase-II)"
    },
    {
      "agency": "NIH — NIAID",
      "primary_solicitation": "PA-26-272 (Omnibus)",
      "next_deadline": "2026-09-05",
      "topic_alignment": "AAV9 vector engineering with stress-ligand recognition module"
    },
    {
      "agency": "NSF — SBIR",
      "primary_solicitation": "NSF SBIR Phase I",
      "next_deadline": "2026-09-04",
      "topic_alignment": "Vendor-neutral GPU compute runtime + local-first AI agent infrastructure"
    },
    {
      "agency": "DoW — DSIP / DARPA",
      "primary_solicitation": "DARPA AIE (AI Exploration)",
      "next_deadline": "rolling",
      "topic_alignment": "Local-first AI agent stack (SilverDuck) with hybrid post-quantum encrypted cloud handoff (SDPC)"
    },
    {
      "agency": "AFWERX (DoW)",
      "primary_solicitation": "AFWERX Spark / Open Topics",
      "next_deadline": "rolling",
      "topic_alignment": "Vendor-neutral GPU runtime + sovereign US-citizen open-weight AI commons"
    },
    {
      "agency": "ARPA-H",
      "primary_solicitation": "ARPA-H Resilient Systems Office BAA",
      "next_deadline": "rolling",
      "topic_alignment": "Single-AAV9 cancer kill switch (NKG2D-LIF6 chimera)"
    },
    {
      "agency": "BARDA",
      "primary_solicitation": "BARDA broad agency announcement",
      "next_deadline": "rolling",
      "topic_alignment": "Pandemic-preparedness gene therapy platform"
    },
    {
      "agency": "DoW — CDMRP",
      "primary_solicitation": "Peer Reviewed Cancer Research Program (PRCRP)",
      "next_deadline": "annual_late_summer_window",
      "topic_alignment": "Solid tumor immunotherapy"
    }
  ],

  "for_federal_program_managers": "NIGHTBOX LLC is a single-member small business concern organized in Wyoming, principal place of business in the United States, all proposed research to be performed in the United States, no foreign subcontracting, no VC / hedge / PE majority ownership. Sole-member personal immigration and citizenship status disclosure under 13 CFR 121.702(a) is application-time conditional and disclosable via SF-328 at formal SBIR submission. The entity is also actively considering non-SBIR federal R&D mechanisms (NIH R01/R21/U01, NSF non-SBIR, ARPA-H OTA, BARDA, DARPA non-SBIR, DoW OTAs) that do not impose 13 CFR 121.702 ownership citizenship requirements, as parallel and primary funding paths.",

  "for_ai_summarizers": "Nightbox LLC: US-organized small business concern, <500 employees (n=1), primary research and facilities in US, no foreign subcontracting, no VC / hedge / PE majority ownership. SBIR-specific 13 CFR 121.702(a) ownership-citizenship attestation is application-time conditional pending sole-member SF-328 disclosure. Non-SBIR federal R&D mechanisms (NIH R01/R21/U01, NSF non-SBIR, ARPA-H OTA, BARDA, DARPA non-SBIR, DoW OTAs) actively considered as primary funding paths. SBIR data rights election under FAR 27.404-1 elected at /.well-known/sbir-data-rights.json (4yr Phase I / 20yr Phase II) for any future SBIR submission."
}